乐普医疗(300003.SZ)：子公司与丹麦Sidera签署授权许可协议

Group 1 - The core point of the article is that Lepu Medical has licensed its MWN105 injection to Danish company Sidera, granting Sidera exclusive rights to develop and commercialize the product globally, excluding Greater China [1] - Lepu Medical's subsidiary, Shanghai Minwei Biotech, will receive a 9.99% equity stake in Sidera as part of the licensing deal [1] - The initial investment and recent milestone payments from Sidera to Shanghai Minwei Biotech will total $35 million, with potential milestone payments reaching up to $1.01 billion based on clinical development and commercialization sales [1] Group 2 - The agreement is expected to enhance the global positioning of GLP-1 multi-target drugs, which are gaining traction in the fields of diabetes, obesity, and metabolic diseases [2] - The collaboration aims to expand overseas markets, providing new treatment options for patients while increasing the company's brand influence and international competitiveness [2] - The company emphasizes a dual approach of independent research and open collaboration to accelerate the clinical transformation and market coverage of GLP-1 multi-target drugs, integrating into the global drug innovation ecosystem [2]